Watch MAZE. Know when insiders buy.
One email the day a filing lands. Free.
Work order
31
FLAG · insiders 25, shorts 37
Insiders, 90 days
−$2.7M
net selling · 0 buys, 18 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.5BP/E —DIV YIELD —FCF YIELD -7.34%REV TTM —NET INCOME −$133.6MNET CASH $163.7M52W 14.97 – 51.83SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$48M | −$44.7M | — | -0.76 | −$15.1M | $107K | −$15.2M | Aug 11 |
| Q1 2026 · Mar 31 | $20M | — | — | −$26.6M | −$24.2M | — | -0.45 | −$39.1M | $93K | −$39.2M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$38.1M | −$34.6M | — | -0.60 | −$27.7M | $34K | −$27.8M | Mar 25 |
| Q3 2025 · Sep 30 | — | — | — | −$33M | −$30.1M | — | -0.66 | −$24.6M | $68K | −$24.7M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$36.5M | −$33.7M | −124.2% | -0.77 | −$30.1M | $393K | −$30.4M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$35.4M | −$32.8M | — | -1.15 | −$29.5M | $299K | −$29.8M | Aug 11 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$29.7M | −$29.6M | — | -1.42 | −$22.5M | $605K | −$23.1M | Mar 25 |
| Q3 2024 · Sep 30 | $2.5M | — | — | −$24.2M | −$24.8M | — | -10.25 | −$23.2M | $103K | −$23.3M | Nov 6 |
| Q2 2024 · Jun 30 | $165M | — | — | $139.6M | $139.1M | — | 3.22 | $145M | $160K | $144.9M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$28M | −$32.5M | — | -13.91 | −$23.4M | $279K | −$23.7M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$142.9M | −$131.1M | — | -3.05 | −$111.9M | $794K | −$112.7M | — | — |
| FY2024 · to Dec 31 | $167.5M | — | $57.6M | $52.2M | 31.2% | 1.25 | $76M | $1.1M | $74.8M | — | — |
Every number comes from Maze Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.